Table 3.

Peak participant ratings (mean ± SEM) of subjective drug effects as measured by the DEQ during the intermittent and daily dosing phases during the first and second session as a function of cumulative oxycodone dose. Participants rated their subjective drug liking by indicating on a scale from -4, corresponding to “Dislike very much,” to 4, corresponding to “Like very much.” Participants rated subjective drug strength and desire to take the dose again on a scale of 0–4, 0 corresponding to “No effects at all” and 4 corresponding to “Very strong effects.”

	Dose (mg/70 kg)	INTERMITTENT		DAILY
		Session 1	Session 2	Session 1	Session 2
LIKE	0	0.1 (0.1)*	0.5 (0.3)*	0.6 (0.3)*	0.1 (0.1)*
	5	0.8 (0.4)#	1.4 (0.4)†	1.1 (0.2)	0.6 (0.2)
	20	1.3 (0.4)	2.1 (0.5)	1.6 (0.4)	1.3 (0.4)
STRONG	0	0.8 (0.4)*	0.8 (0.3)*	0.7 (0.2)*	0.8 (0.3)*
	5	1.6 (0.8)#,†	2.2 (0.3)†	2.1 (0.3)#	0.9 (0.3)
	20	3.1 (0.2)	3.3 (0.2)	3.3 (0.2)	2.8 (0.3)
TAKE AGAIN	0	1.9 (0.5)#	1.3 (0.4)*	1.7 (0.4)	1.4 (0.3)
	5	1.9 (0.5)	2.2 (0.5)†	1.7 (0.4)#	1.4 (0.3)
	20	1.8 (0.5)	2.1 (0.5)	2.0 (0.4)	1.3 (0.4)

Significant differences between placebo and oxycodone (cumulative doses of 5 and 20 mg/70kg) within a session are indicated by * (p ≤ 0.05). Within each phase, significant differences between sessions in placebo or oxycodone effects are indicated by # (p ≤ 0.05). Between phases, significant differences between corresponding sessions for placebo or oxycodone effects are indicated by ^† (p ≤ 0.05).